Pfizer and Biontech announced that their Covid-19 vaccine is more than 90 % effective, following the “success” of the first interim analysis of their phase 3 trial.
Thus, its candidate for a vaccine based on mRNA, BNT162b2 against SARS-COV-2, confirmed its efficacy against the coronavirus in participants without previous evidence of infection, according to the first provisional efficacy analysis carried out on November 8th.
The tests were conducted on a total of 43,538 participants and the analysis has evaluated 94 confirmed cases of Covid-19 in trial participants.
Following these results, Pfizer President and CEO Albert Bourla said it is “a great day for science and humanity. The first results from our Phase 3 Covid-19 vaccine trial provide initial evidence of the ability to prevent the disease.”
Pfizer president insisted that the first interim analysis of its global phase 3 study “provides evidence that a vaccine can effectively prevent Covid-19. This is a victory for innovation, science and a global collaborative effort.”
Based on current projections, the company expects to produce up to 50 million doses of vaccines globally in 2020 and up to 1.3 billion doses in 2021.